Insulet Corp.
Insulet Corporation (PODD)
Overview
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, founded in 2000 and publicly traded since 2007. It designs, manufactures, and sells tubeless, wearable insulin delivery systems for people with insulin-dependent diabetes, marketed under the Omnipod brand, and operates in the U.S. and internationally. The company employs roughly 5,400 people and has grown rapidly, with revenue rising from about $1.1 billion in 2021 to over $2.7 billion in 2025 (trailing revenue around $3.0 billion), and a market capitalization in the $10 billion range. Insulet is classified in the Medical Devices industry within the S&P 500's Healthcare sector.
What They Do & How They Make Money
Insulet's business is built around its Omnipod platform, a tubeless, waterproof, disposable insulin "pod" that a patient wears on the body and that automatically delivers insulin according to a programmed or algorithm-driven schedule, eliminating the tubing and separate pump-and-catheter setup used by traditional insulin pumps. The core revenue model is recurring and consumable-driven: patients (largely people with Type 1 diabetes, and a growing base with Type 2 diabetes) replace each pod every few days, so once a patient is prescribed and onboarded onto Omnipod, they generate a steady, high-frequency stream of pod purchases — a durable annuity-like revenue base rather than a one-time device sale. Insulet's flagship product, Omnipod 5, integrates a proprietary dosing algorithm directly into the pod and communicates wirelessly with continuous glucose monitors (from partners such as Dexcom and Abbott) to automatically adjust insulin delivery in a closed-loop ("automated insulin delivery") system, reducing the burden of manual dosing decisions. The company also sells the Bluetooth-enabled Omnipod DASH system (controlled via a smartphone-like personal diabetes manager or a mobile app) and continues to phase out older, non-connected pod technology. Growth comes from three main levers: increasing U.S. Type 1 patient penetration and, increasingly, expansion into the much larger Type 2 diabetes population; international expansion (particularly in Europe and other markets); and steady annual pod volume growth from the existing, growing patient base. Separately, Insulet has a smaller contract-manufacturing relationship in which it produces pods for Amgen's Neulasta Onpro delivery device, a non-diabetes application of its wearable-pod technology.
Business Segments
Insulet does not report multiple distinct operating segments in the way a diversified conglomerate does; it operates and reports essentially as a single insulin-delivery-systems business, with revenue commonly broken out by geography and product line in its financial disclosures:
- U.S. Omnipod revenue — sales of Omnipod 5 and Omnipod DASH systems and pods to U.S. patients, historically the largest single revenue driver, split between Type 1 and a fast-growing Type 2 diabetes patient base.
- International Omnipod revenue — sales outside the U.S., a smaller but faster-growing portion of the business as Insulet expands access and reimbursement in new countries.
- Drug delivery (Amgen partnership) — pod-based drug delivery technology supplied to Amgen for the Neulasta Onpro device; a small, non-core but stable supplementary revenue stream that leverages the same core pod-manufacturing technology.
Omnipod product revenue (U.S. and international combined) makes up the substantial majority of total revenue, with the Amgen drug-delivery business contributing a small single-digit percentage.
Competitors
- Insulin pump/automated insulin delivery devices: Tandem Diabetes Care (t:slim X2 and Tandem Mobi systems) and Medtronic's MiniMed insulin pump business are the primary direct competitors in durable and semi-durable insulin pump technology.
- Continuous glucose monitoring (adjacent/partner-competitor): Dexcom and Abbott (FreeStyle Libre) are primarily CGM partners whose sensors integrate with Omnipod 5, but they also compete indirectly for overall "diabetes technology" spend and increasingly bundle their own automated-insulin-delivery partnerships.
- Traditional insulin delivery: multiple daily injection therapy (insulin pens and vials) from insulin manufacturers such as Eli Lilly, Novo Nordisk, and Sanofi represents the largest overall alternative to any pump-based system, since the majority of insulin-using patients worldwide still use injections rather than pumps.
- Emerging/international pump makers: smaller regional insulin pump and patch-pump companies competing on cost or specific market niches outside the U.S.
Competitive Position
Insulet's primary competitive advantage is its tubeless, fully disposable pod design, which differentiates Omnipod from tubed, durable pump competitors like Tandem and Medtronic — many patients and caregivers (especially in pediatric populations) prefer the discretion, simplicity, and lack of external tubing that Omnipod offers. The recurring, subscription-like nature of pod consumption creates a sticky, high-visibility revenue base once a patient is established on the platform, and Insulet's continued algorithm improvements (Omnipod 5) and CGM integrations keep the product competitive with newer automated insulin delivery entrants. The large and still-underpenetrated Type 2 diabetes population represents a significant incremental growth opportunity beyond the company's traditional Type 1 base, and international markets offer a long runway as reimbursement expands.
Key risks include intensifying competition from Tandem and Medtronic, both of which continue to innovate their own automated insulin delivery and tubeless/patch offerings, and from the CGM makers themselves, some of which have explored deeper integration or their own delivery partnerships. Insulet depends on continued favorable insurance/reimbursement coverage for its devices and consumables, and any pricing or coverage pressure from payers could affect margins or patient access. The company also faces manufacturing and supply chain execution risk given the scale required to produce a high volume of disposable pods reliably, regulatory risk typical of Class II/III medical devices, and — as reflected in a 2025 stock pullback after the company lowered its Omnipod growth outlook and reported a decline in full-year net income despite revenue growth — sensitivity to any deceleration in patient additions or U.S. Type 2 uptake could weigh on its currently premium growth-stock valuation.